Sensorion: Differentiated OTOF and GJB2 Gene Therapy Pipeline Positions Company for Best-in-Class Outcomes and Attractive Risk-Reward Into 2026

Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Sensorion SAS, boosting the price target to €4.00.

Joseph Pantginis has given his Buy rating due to a combination of factors that highlight Sensorion’s strategic positioning and clinical potential heading into 2026. He sees the company’s focus shifting from being first-to-market to demonstrating superior, best-in-class clinical outcomes, especially as Regeneron is likely to secure the initial FDA approval in the OTOF hearing loss segment. Pantginis views the upcoming 6‑month data readout from Cohort 2 of the Phase 1/2 Audiogene trial in 1Q26 as a pivotal catalyst that could validate SENS‑501’s differentiated, late-maturing hearing recovery profile and support key regulatory interactions, including a potential end-of-Phase 2 meeting by mid‑2026. He believes that if Sensorion can show more robust improvement in hearing thresholds between months three and six compared with competitors, the company could carve out a best‑in‑class niche despite not being first to market.
Additionally, Pantginis highlights the GJB2 gene therapy program as a significant value contributor, with a clinical trial application filing expected in 1Q26, combining meaningful first‑mover potential with a large target population. He interprets management’s refined strategy—emphasizing durability of response, extended follow‑up, and a more comprehensive Audiogene data release in 1Q26—as evidence of disciplined execution aligned with the evolving competitive landscape. Taken together, the prospect of differentiated OTOF data, the advancing GJB2 program, and the possibility that Sensorion becomes a strategic acquisition target underpin his conviction that the risk‑reward profile is attractive at current levels, supporting a Buy recommendation.